Sanford C. Bernstein Upgrades Shire (SHPG) to “Outperform”

Shire (NASDAQ:SHPG) was upgraded by Sanford C. Bernstein from a “market perform” rating to an “outperform” rating in a report released on Wednesday, MarketBeat reports.

A number of other brokerages also recently commented on SHPG. Piper Jaffray Companies restated a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 target price on Shire and gave the company a “buy” rating in a report on Wednesday, January 3rd. Liberum Capital restated a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Cowen set a $225.00 target price on Shire and gave the company a “buy” rating in a report on Friday, January 5th. Finally, ValuEngine downgraded Shire from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $212.50.

Shares of Shire (NASDAQ SHPG) traded up $0.19 during mid-day trading on Wednesday, reaching $132.86. The company’s stock had a trading volume of 2,040,000 shares, compared to its average volume of 1,510,000. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire has a 12-month low of $123.73 and a 12-month high of $192.15. The company has a market capitalization of $40,100.00, a P/E ratio of 25.02, a P/E/G ratio of 0.71 and a beta of 1.41.

Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.41% and a net margin of 10.95%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the company posted $3.37 earnings per share. The business’s revenue was up 8.9% on a year-over-year basis. equities analysts forecast that Shire will post 15 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. SeaCrest Wealth Management LLC purchased a new stake in Shire in the fourth quarter worth $107,000. Amica Retiree Medical Trust purchased a new stake in Shire in the fourth quarter worth $120,000. BB&T Investment Services Inc. grew its stake in Shire by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 786 shares during the period. Avestar Capital LLC purchased a new stake in Shire in the fourth quarter worth $116,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in Shire in the third quarter worth $159,000. 20.74% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Sanford C. Bernstein Upgrades Shire (SHPG) to “Outperform”” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/14/sanford-c-bernstein-upgrades-shire-shpg-to-outperform.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply